Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and The Cooper Companies (COO) have performed compared to their sector so…
2,800€
-0,36%
Echtzeit-Aktienkurs Adagene Inc. (ADRs)
Bid:
Ask:
Nachrichten zur Adagene Inc. (ADRs) Aktie
Form 6-K Adagene Inc. For: May 04
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 6-K Adagene Inc. For: Apr 28
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Adagene Announces Updates to its Board of Directors
SAN DIEGO and SUZHOU, China, April 28, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven,…
Expert Ratings for Adagene
Latest Ratings for ADAG
DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsOverweight Jan 2022Morgan StanleyMaintainsOverweight Jul 2021Morgan StanleyMaintainsOverweight
View…
Form 6-K Adagene Inc. For: Apr 18
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors
- Results of dose escalation portion from phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies, including confirmed clinical…
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and Alcon (ALC) have performed compared to their sector so far this…
Form 6-K Adagene Inc. For: Mar 28
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Adagene ADR GAAP EPS of -$1.48 beats by $0.04, revenue of $9.29M beats by $0.45M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update
- Clinical data for wholly-owned anti-CTLA-4 franchise show best-in-class safety profiles for unmasked and masked candidates, unlocking the full therapeutic benefit…
Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April
- Clinical posters detail results of dose escalation portion of phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies,…
Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board
- Brings deep insight in tumor-specific Treg depletion for anti-CTLA-4 therapies delivered intratumorally to overcome dose dependent toxicities -...…
Form 6-K Adagene Inc. For: Jan 09
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9
SAN DIEGO and SUZHOU, China, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company…
Adagene adds 12% on clinical trial collaboration with Roche
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 6-K Adagene Inc. For: Dec 16
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Adagene Appoints Cuong Do to Board of Directors and Audit Committee
SAN DIEGO and SUZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company…
Form 6-K Adagene Inc. For: Nov 21
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors
- Interim phase 1b/2 data report safety profile of ADG116 across dosing levels, with repeat dosing of more than four…